Cargando…

Extensive Anti-CoA Immunostaining in Alzheimer’s Disease and Covalent Modification of Tau by a Key Cellular Metabolite Coenzyme A

Alzheimer’s disease (AD) is a neurodegenerative disorder, accounting for at least two-thirds of dementia cases. A combination of genetic, epigenetic and environmental triggers is widely accepted to be responsible for the onset and development of AD. Accumulating evidence shows that oxidative stress...

Descripción completa

Detalles Bibliográficos
Autores principales: Lashley, Tammaryn, Tossounian, Maria-Armineh, Costello Heaven, Neve, Wallworth, Samantha, Peak-Chew, Sew, Bradshaw, Aaron, Cooper, J. Mark, de Silva, Rohan, Srai, Surjit Kaila, Malanchuk, Oksana, Filonenko, Valeriy, Koopman, Margreet B., Rüdiger, Stefan G. D., Skehel, Mark, Gout, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554225/
https://www.ncbi.nlm.nih.gov/pubmed/34720880
http://dx.doi.org/10.3389/fncel.2021.739425
_version_ 1784591749938675712
author Lashley, Tammaryn
Tossounian, Maria-Armineh
Costello Heaven, Neve
Wallworth, Samantha
Peak-Chew, Sew
Bradshaw, Aaron
Cooper, J. Mark
de Silva, Rohan
Srai, Surjit Kaila
Malanchuk, Oksana
Filonenko, Valeriy
Koopman, Margreet B.
Rüdiger, Stefan G. D.
Skehel, Mark
Gout, Ivan
author_facet Lashley, Tammaryn
Tossounian, Maria-Armineh
Costello Heaven, Neve
Wallworth, Samantha
Peak-Chew, Sew
Bradshaw, Aaron
Cooper, J. Mark
de Silva, Rohan
Srai, Surjit Kaila
Malanchuk, Oksana
Filonenko, Valeriy
Koopman, Margreet B.
Rüdiger, Stefan G. D.
Skehel, Mark
Gout, Ivan
author_sort Lashley, Tammaryn
collection PubMed
description Alzheimer’s disease (AD) is a neurodegenerative disorder, accounting for at least two-thirds of dementia cases. A combination of genetic, epigenetic and environmental triggers is widely accepted to be responsible for the onset and development of AD. Accumulating evidence shows that oxidative stress and dysregulation of energy metabolism play an important role in AD pathogenesis, leading to neuronal dysfunction and death. Redox-induced protein modifications have been reported in the brain of AD patients, indicating excessive oxidative damage. Coenzyme A (CoA) is essential for diverse metabolic pathways, regulation of gene expression and biosynthesis of neurotransmitters. Dysregulation of CoA biosynthesis in animal models and inborn mutations in human genes involved in the CoA biosynthetic pathway have been associated with neurodegeneration. Recent studies have uncovered the antioxidant function of CoA, involving covalent protein modification by this cofactor (CoAlation) in cellular response to oxidative or metabolic stress. Protein CoAlation has been shown to both modulate the activity of modified proteins and protect cysteine residues from irreversible overoxidation. In this study, immunohistochemistry analysis with highly specific anti-CoA monoclonal antibody was used to reveal protein CoAlation across numerous neurodegenerative diseases, which appeared particularly frequent in AD. Furthermore, protein CoAlation consistently co-localized with tau-positive neurofibrillary tangles, underpinning one of the key pathological hallmarks of AD. Double immunihistochemical staining with tau and CoA antibodies in AD brain tissue revealed co-localization of the two immunoreactive signals. Further, recombinant 2N3R and 2N4R tau isoforms were found to be CoAlated in vitro and the site of CoAlation mapped by mass spectrometry to conserved cysteine 322, located in the microtubule binding region. We also report the reversible H(2)O(2)-induced dimerization of recombinant 2N3R, which is inhibited by CoAlation. Moreover, CoAlation of transiently expressed 2N4R tau was observed in diamide-treated HEK293/Pank1β cells. Taken together, this study demonstrates for the first time extensive anti-CoA immunoreactivity in AD brain samples, which occurs in structures resembling neurofibrillary tangles and neuropil threads. Covalent modification of recombinant tau at cysteine 322 suggests that CoAlation may play an important role in protecting redox-sensitive tau cysteine from irreversible overoxidation and may modulate its acetyltransferase activity and functional interactions.
format Online
Article
Text
id pubmed-8554225
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85542252021-10-30 Extensive Anti-CoA Immunostaining in Alzheimer’s Disease and Covalent Modification of Tau by a Key Cellular Metabolite Coenzyme A Lashley, Tammaryn Tossounian, Maria-Armineh Costello Heaven, Neve Wallworth, Samantha Peak-Chew, Sew Bradshaw, Aaron Cooper, J. Mark de Silva, Rohan Srai, Surjit Kaila Malanchuk, Oksana Filonenko, Valeriy Koopman, Margreet B. Rüdiger, Stefan G. D. Skehel, Mark Gout, Ivan Front Cell Neurosci Neuroscience Alzheimer’s disease (AD) is a neurodegenerative disorder, accounting for at least two-thirds of dementia cases. A combination of genetic, epigenetic and environmental triggers is widely accepted to be responsible for the onset and development of AD. Accumulating evidence shows that oxidative stress and dysregulation of energy metabolism play an important role in AD pathogenesis, leading to neuronal dysfunction and death. Redox-induced protein modifications have been reported in the brain of AD patients, indicating excessive oxidative damage. Coenzyme A (CoA) is essential for diverse metabolic pathways, regulation of gene expression and biosynthesis of neurotransmitters. Dysregulation of CoA biosynthesis in animal models and inborn mutations in human genes involved in the CoA biosynthetic pathway have been associated with neurodegeneration. Recent studies have uncovered the antioxidant function of CoA, involving covalent protein modification by this cofactor (CoAlation) in cellular response to oxidative or metabolic stress. Protein CoAlation has been shown to both modulate the activity of modified proteins and protect cysteine residues from irreversible overoxidation. In this study, immunohistochemistry analysis with highly specific anti-CoA monoclonal antibody was used to reveal protein CoAlation across numerous neurodegenerative diseases, which appeared particularly frequent in AD. Furthermore, protein CoAlation consistently co-localized with tau-positive neurofibrillary tangles, underpinning one of the key pathological hallmarks of AD. Double immunihistochemical staining with tau and CoA antibodies in AD brain tissue revealed co-localization of the two immunoreactive signals. Further, recombinant 2N3R and 2N4R tau isoforms were found to be CoAlated in vitro and the site of CoAlation mapped by mass spectrometry to conserved cysteine 322, located in the microtubule binding region. We also report the reversible H(2)O(2)-induced dimerization of recombinant 2N3R, which is inhibited by CoAlation. Moreover, CoAlation of transiently expressed 2N4R tau was observed in diamide-treated HEK293/Pank1β cells. Taken together, this study demonstrates for the first time extensive anti-CoA immunoreactivity in AD brain samples, which occurs in structures resembling neurofibrillary tangles and neuropil threads. Covalent modification of recombinant tau at cysteine 322 suggests that CoAlation may play an important role in protecting redox-sensitive tau cysteine from irreversible overoxidation and may modulate its acetyltransferase activity and functional interactions. Frontiers Media S.A. 2021-10-15 /pmc/articles/PMC8554225/ /pubmed/34720880 http://dx.doi.org/10.3389/fncel.2021.739425 Text en Copyright © 2021 Lashley, Tossounian, Costello Heaven, Wallworth, Peak-Chew, Bradshaw, Cooper, de Silva, Srai, Malanchuk, Filonenko, Koopman, Rüdiger, Skehel and Gout. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Lashley, Tammaryn
Tossounian, Maria-Armineh
Costello Heaven, Neve
Wallworth, Samantha
Peak-Chew, Sew
Bradshaw, Aaron
Cooper, J. Mark
de Silva, Rohan
Srai, Surjit Kaila
Malanchuk, Oksana
Filonenko, Valeriy
Koopman, Margreet B.
Rüdiger, Stefan G. D.
Skehel, Mark
Gout, Ivan
Extensive Anti-CoA Immunostaining in Alzheimer’s Disease and Covalent Modification of Tau by a Key Cellular Metabolite Coenzyme A
title Extensive Anti-CoA Immunostaining in Alzheimer’s Disease and Covalent Modification of Tau by a Key Cellular Metabolite Coenzyme A
title_full Extensive Anti-CoA Immunostaining in Alzheimer’s Disease and Covalent Modification of Tau by a Key Cellular Metabolite Coenzyme A
title_fullStr Extensive Anti-CoA Immunostaining in Alzheimer’s Disease and Covalent Modification of Tau by a Key Cellular Metabolite Coenzyme A
title_full_unstemmed Extensive Anti-CoA Immunostaining in Alzheimer’s Disease and Covalent Modification of Tau by a Key Cellular Metabolite Coenzyme A
title_short Extensive Anti-CoA Immunostaining in Alzheimer’s Disease and Covalent Modification of Tau by a Key Cellular Metabolite Coenzyme A
title_sort extensive anti-coa immunostaining in alzheimer’s disease and covalent modification of tau by a key cellular metabolite coenzyme a
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554225/
https://www.ncbi.nlm.nih.gov/pubmed/34720880
http://dx.doi.org/10.3389/fncel.2021.739425
work_keys_str_mv AT lashleytammaryn extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT tossounianmariaarmineh extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT costelloheavenneve extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT wallworthsamantha extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT peakchewsew extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT bradshawaaron extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT cooperjmark extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT desilvarohan extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT sraisurjitkaila extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT malanchukoksana extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT filonenkovaleriy extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT koopmanmargreetb extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT rudigerstefangd extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT skehelmark extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea
AT goutivan extensiveanticoaimmunostaininginalzheimersdiseaseandcovalentmodificationoftaubyakeycellularmetabolitecoenzymea